Two prospective trials of immunotherapy in thyroid cancer, one of them negative, provided support for precision-medicine approaches that include immunotherapy. A trial of atezolizumab (Tecentriq ...

Anaplastic thyroid cancer has historically had very poor prognoses, with nearly 100% of cases being fatal. In stage IVB, the current standard of care has involved multimodal therapy, including ...

Atezolizumab Plus Targeted Agents Shows Promise in Anaplastic Thyroid Carcinoma - Medscape - October 28, 2024. Comments Commenting is limited to medical professionals.

Its lead candidate, AIC100, is currently in a Phase 1 study to treat patients with advanced thyroid cancers including advanced differentiated thyroid cancer (ADTC) and anaplastic thyroid cancer (ATC).

Patients with anaplastic thyroid carcinoma need treatments that work fast, and we saw promising results with this combination treatment approach. The takeaway from this study is that immunotherapy ...

Source Reference: Cabanillas ME, et al "Anti-programmed death ligand 1 plus targeted therapy in anaplastic thyroid carcinoma: A nonrandomized clinical trial" JAMA Oncol 2024; DOI: 10.1001 ...